Replies to post #193934 on Biotech Values

[biocqr]

EPIX > ESSA now enrolling pts in mCRPC study..

https://clinicaltrials.gov/ct2/show/NCT02606123

ESSA Announces Enrollment of First Patient in Phase 1/2 Trial
http://seekingalpha.com/pr/15479086-essa-announces-enrollment-of-first-patient-in-phase-1-2-trial

HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. (ESSQF) ("ESSA" or the "Company") (TSX: EPI; NASDAQ (NBI): EPIX) announced today that the first patient has been enrolled in ESSA (EPIX)'s Phase 1/2 clinical study of EPI-506 as a treatment for metastatic castration-resistant prostate cancer ("mCRPC").

In the Phase 1/2 clinical trial, ESSA intends to demonstrate the safety, tolerability, maximum tolerated-dose, pharmacokinetics, and efficacy of EPI-506 in prostate cancer patients who have failed abiraterone or enzalutamide or both, the current standard-of-care drugs in mCRPC. The trial is expected to enroll approximately 150 subjects across the United States and Canada.

"Patients with metastatic CRPC who have failed abiraterone and/or enzalutamide currently represent a large unmet medical need," said Dr. Frank Perabo, ESSA's Chief Medical Officer. "The novel mechanism of action of EPI-506 was developed specifically to overcome resistance to these current drugs."

As part of the clinical study, ESSA will collect molecular biomarker information which may provide useful context in understanding patient outcomes. Androgen receptor splice variant V7 data will be included in such information.